Translate bio, inc. (TBIO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Collaboration revenue

4,654

3,890

1,266

1,174

1,474

-

238

-

-

-

-

Operating expenses:
Research and development

21,439

25,026

17,295

16,625

17,423

17,170

12,933

15,219

12,702

11,097

13,506

General and administrative

7,458

7,347

6,881

7,850

6,554

5,879

5,957

5,991

4,779

3,607

3,125

Change in fair value of contingent consideration

-9,452

3,256

-19,834

4,889

11,702

-14,569

26,829

7,852

4,908

6,132

2,324

Impairment of intangible asset

-

-

18,559

-

-

-

-

-

-

-

-

Total operating expenses

19,445

35,629

22,901

29,364

35,679

8,480

45,719

29,062

22,389

20,836

18,955

Loss from operations

-14,791

-31,739

-21,635

-28,190

-34,205

-7,298

-45,481

-29,062

-22,389

-20,836

-18,955

Other income (expense):
Interest income, net

509

703

428

358

521

825

318

91

89

72

79

Other expense

-

-

-20

-

-

-2

-7

-32

-12

-

73

Total other income (expense), net

-

-

408

358

-

823

311

59

77

72

152

Loss before benefit from income taxes

-14,282

-31,036

-21,227

-27,832

-33,684

-6,475

-45,170

-29,003

-22,312

-20,764

-18,803

Benefit from income taxes

0

0

0

0

-486

-438

-2,524

-1,500

-1,103

-2,299

-870

Net loss

-14,282

-31,036

-21,227

-27,832

-33,198

-6,037

-42,646

-27,503

-21,209

-18,465

-17,933

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

0

0

459

185

180

192

Net loss attributable to common stockholders

-

-

-21,227

-27,832

-

-6,037

-42,646

-27,962

-21,394

-18,645

-17,741

Net loss per share—basic and diluted

-0.24

-0.48

-0.41

-0.57

-0.74

2.72

-0.97

-3.04

-2.35

-2.40

-2.31

Weighted average common shares outstanding—basic and diluted

60,008

60,136

51,891

48,749

45,004

45,466

44,036

9,187

9,091

7,781

7,676